Novo Nordisk

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments.

CEO

Maziar Mike Doustdar

CEOMaziar Mike Doustdar

Employees

68,794

Employees68,794

Headquarters

Bagsværd, Capital Region

HeadquartersBagsværd, Capital Region

Founded

1923

Founded1923

Employees

68,794

Employees68,794

NVO Key Statistics

Market cap

168.65B

Market cap168.65B

Price-Earnings ratio

9.35

Price-Earnings ratio9.35

Dividend yield

3.21%

Dividend yield3.21%

Average volume

18.81M

Average volume18.81M

High today

$38.77

High today$38.77

Low today

$37.88

Low today$37.88

Open price

$38.04

Open price$38.04

Volume

21.56M

Volume21.56M

52 Week high

$64.16

52 Week high$64.16

52 Week low

$35.12

52 Week low$35.12

NVO News

The Motley Fool 6h

Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy

Novo Nordisk (NVO -1.04%) has a problem. The company generates most of its revenue from its diabetes and obesity products, but stiff competition from Eli Lilly...

Benzinga 12h

Novo Nordisk Says Next-Gen Obesity Drug Reduces Food Noise, Drives Weight Loss

Novo Nordisk A/S (NYSE:NVO) on Wednesday revealed new clinical and real-world data at the 2026 European Association for the Study of Diabetes (EASD) Annual Meet...

TipRanks 13h

Novo Nordisk Opens a New Front in Cardiometabolic Care With Early-Stage Anti-Inflammatory Study

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Novo Nordisk Explores New Anti-Inflammatory Pathway for Heart and Metabolic Health. Thi...

More NVO News

TipRanks 13h

Novo Nordisk Tests Cagrisema Switch Strategy to Strengthen Its Diabetes Franchise

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Novo Nordisk Studies Key Switch From Ozempic to Cagrisema for Type 2 Diabetes The stud...

Nasdaq 1d

Novo Nordisk Gives Uninspiring Outlook

Investors were hopeful for a better growth estimate. Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they...

Zacks 1d

Novo Nordisk Dips More Than Broader Market: What You Should Know

Novo Nordisk (NVO Quick QuoteNVO - Free Report) closed at $38.31 in the latest trading session, marking a -1.03% move from the prior day. The stock traile...

Benzinga 2d

Tirzepatide or Wegovy? Novo Nordisk Says Higher Semaglutide Dose Shows Cardiovascular Edge Over Eli Lilly's Tirzepatide

Novo Nordisk A/S (NYSE:NVO) announced on Tuesday new real-world evidence demonstrating that escalating semaglutide dosage reduces major adverse cardiovascular e...

TipRanks 2d

Novo Nordisk enters into license agreement with Hengrui Pharma on HRS-1596

The company stated: “Novo Nordisk (NVO) announced that it has entered into a license agreement with Hengrui Pharma for HRS-1596, a phase 1-ready glucagon-like p...

TipRanks 2d

Novo Nordisk announces retrospective RWE on Ozempic in type 2 diabets

Novo Nordisk (NVO) announced new retrospective real-world evidence in adults with type 2 diabetes treated with once-weekly semaglutide injection 1 mg. In the an...

MarketWatch 2d

Novo Nordisk strikes second licensing deal since frosty capital-markets day

Novo Nordisk on Tuesday struck its second licensing deal since receiving a poor reception from investors after presenting its long-term strategy. Novo Nordisk...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.